We found for
Realising The Broader Value of Vaccines in the UK: Ready for Prime Time?
The Broader Value of Vaccines: The Return on Investment From a Governmental Perspective
Realising the Broader Value of Vaccines in the UK
NICE ‘Optimised’ Decisions: What is the Recommended Level of Patient Access?
Delivering the 2.4 Percent: Unlocking UK Pharma R&D Investment through Evidence-Based Policies
International Cost-Effectiveness Thresholds and Modifiers for HTA Decision Making
Exploring Variations in the Opportunity Cost Cost-effectiveness Threshold by Clinical Area: Results from a Feasibility Study in England
Public Preferences for Health Gains and Cures: A Discrete Choice Experiment
Measurement of Medicines Expenditure in the Context of the 2014-18 PPRS
The Impact of New Medicines in the NHS: 70 Years of Innovation
Issues Surrounding the Estimation of the Opportunity Cost of Adopting a New Health Care Technology: Areas for Further Research
Establishing a Reasonable Price for an Orphan Drug
Appraising Ultra-Orphan Drugs: Is Cost-Per-QALY Appropriate? A Review of the Evidence
Shaping the Research Agenda to Estimate Cost-effectiveness Thresholds for Decision Making
Assessing the Use of Multi-indication Medicines: A Review of Current Data Capabilities in the UK
